My primary interest is SNT 6302 ,,, Topical Creams are far simpler to commercialise with lower regulatory requirements being dermal application not Ingestion or Intravenous.
SNT 6302 will be a highly visual trial easily understood by investors ...
IMHO this company is currently undervalued having the ability to progress to multiple (4) Phase II Trials .. News Flow needs lifting , myself and several other Traders & Investors have been buying SNT .. now in my top 5 Holdings,, NZT
https://biotechdispatch.com.au/news/pharmaxis-reports-positive-results-from-trial-of-pxs6302
Trend line looked to show a finish of last week @4.5c peaked @4.6 but some larger sales on Thursday and Friday pulled back the SP?
Ann: Phase 2 blood cancer trial fully recruited, page-29
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
-0.002(4.88%) |
Mkt cap ! $53.55M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.1¢ | 3.9¢ | $69.92K | 1.738M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 333839 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 210000 | 2 |
View Market Depth
| Last trade - 13.48pm 12/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |